Loading…
Aptus Pharma (BSE 544529)₹471.25+1.34%Pharmaceuticals
In the Mar 2026 quarter (standalone), Aptus Pharma reported sales of ₹32.14 Cr, up 117.3% from Mar 2025, and net profit of ₹2.88 Cr, up 60.0% year on year. For the year to Mar 2026, sales were ₹46.49 Cr and net profit ₹4.63 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 9.75 | 14.79 | 14.37 | 32.14 |
| Expenses | 7.77 | 11.91 | 11.43 | 27.66 |
| Operating Profit | 1.99 | 2.88 | 2.94 | 4.51 |
| OPM % | 20.3% | 19.4% | 20.4% | 14.0% |
| Other Income | 0.00 | 0.07 | 0.00 | 0.11 |
| Interest | 0.12 | 0.37 | 0.42 | 0.34 |
| Depreciation | 0.10 | 0.14 | 0.15 | 0.24 |
| Profit before tax | 1.77 | 2.45 | 2.36 | 4.03 |
| Tax % | 25.5% | 26.2% | 25.5% | 28.6% |
| Net Profit | 1.32 | 1.80 | 1.76 | 2.88 |
| EPS (Rs) | 5.22 | 1.42 | 1.01 | 1.66 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 13.89 | 17.78 | 24.54 | 46.49 |
| Expenses | 13.26 | 16.26 | 19.68 | 39.06 |
| Operating Profit | 0.63 | 1.55 | 4.86 | 7.46 |
| OPM % | 4.5% | 8.6% | 19.7% | 16.0% |
| Other Income | 0.00 | 0.02 | 0.07 | 0.12 |
| Interest | 0.15 | 0.25 | 0.48 | 0.79 |
| Depreciation | 0.17 | 0.20 | 0.26 | 0.40 |
| Profit before tax | 0.31 | 1.13 | 4.20 | 6.38 |
| Tax % | 33.3% | 28.5% | 26.0% | 27.4% |
| Net Profit | 0.20 | 0.81 | 3.11 | 4.63 |
| EPS (Rs) | 2.37 | 9.97 | 2.47 | 2.68 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.29 | 0.29 | 4.99 | 6.85 |
| Reserves | 0.66 | 1.46 | 1.96 | 16.45 |
| Borrowings | 2.23 | 5.32 | 10.36 | 7.19 |
| Other Liabilities | 3.03 | 2.95 | 4.58 | 12.94 |
| Total Liabilities | 6.21 | 10.02 | 21.89 | 43.43 |
| Fixed Assets | 0.53 | 0.64 | 1.00 | 2.78 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 5.68 | 9.38 | 20.89 | 40.65 |
| Inventories | 2.31 | 3.44 | 7.09 | 13.62 |
| Trade receivables | 2.41 | 3.36 | 5.65 | 18.80 |
| Cash & equivalents | 0.55 | 0.92 | 5.22 | 1.04 |
| Total Assets | 6.21 | 10.02 | 21.89 | 43.43 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from operating activity | −0.17 | −2.16 | −1.83 | −6.85 |
| Cash from investing activity | −0.36 | −0.31 | −0.55 | −6.39 |
| Cash from financing activity | 0.80 | 2.85 | 6.67 | 9.03 |
| Net cash flow | 0.29 | 0.39 | 4.31 | −4.20 |
| Capex | 0.34 | 0.32 | 0.61 | 2.18 |
| Free cash flow | −0.54 | −2.51 | −2.47 | −9.08 |
| CFO / OP % | −10.1% | −119.0% | −15.0% | −76.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 63 | 69 | 84 | 147 |
| Inventory days | 177 | 185 | 286 | 233 |
| Days payable | 104 | 72 | 53 | 139 |
| Cash conversion cycle | 134 | 179 | 315 | 239 |
| Working capital days | 52 | 67 | 36 | 117 |
| ROCE % | — | 26.4% | 38.2% | 30.0% |
For the Mar 2026 quarter, Aptus Pharma reported sales of ₹32.14 Cr, up 117.3% year on year and net profit of ₹2.88 Cr, up 60.0% year on year. The operating margin was 14.0%.
Aptus Pharma's sales for the year to Mar 2026 were ₹46.49 Cr.
Net profit for the year to Mar 2026 was ₹4.63 Cr. Earnings per share over the same trailing period were ₹2.68.
Aptus Pharma reported borrowings of ₹7.19 Cr at Mar 2026, against cash and equivalents of ₹1.04 Cr.
Cash from operations was −₹6.85 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹9.08 Cr.